Yan Zhang1, Xiaohua Liao1, Yupeng Jiang1, Xin Lv1, Yue Yu1, Qin Dai1, Liyun Ao1, Lijian Tao1, Zhangzhe Peng2. 1. Department of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. 2. Department of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. pengzhangzhe@csu.edu.cn.
Abstract
BACKGROUND: AarF domain-containing kinase 4 (ADCK4)-associated glomerulopathy is a mitochondrial nephropathy caused by mutations in the ADCK4 gene, which disrupt coenzyme Q10 biosynthesis. CASE PRESENTATION: We report the case of a 25-year-old female patient with ADCK4-associated glomerulopathy presenting with proteinuria (and with no additional systemic symptoms). A known missense substitution c.737G > A (p.S246N) and a novel frameshift c.577-600del (p.193-200del) mutation were found. We followed the patient for 24 months during supplementation with coenzyme Q10 (20 mg/kg/d - 30 mg/kg/d) and describe the clinical course. In addition, we measured serum and urine coenzyme Q10 levels before and after coenzyme Q10 supplementation and compared them with those of healthy control subjects. The patient's urinary coenzyme Q10 to creatinine ratio was higher than that of healthy controls before coenzyme Q10 supplementation, but decreased consistently with proteinuria after coenzyme Q10 supplementation. CONCLUSIONS: Although the use of urinary coenzyme Q10 as a diagnostic biomarker and predictor of clinical remission in patients with ADCK4-associated glomerulopathy should be confirmed by larger studies, we recommend measuring urinary coenzyme Q10 in patients with isolated proteinuria of unknown cause, since it may provide a diagnostic clue to mitochondrial nephropathy.
BACKGROUND: AarF domain-containing kinase 4 (ADCK4)-associated glomerulopathy is a mitochondrial nephropathy caused by mutations in the ADCK4 gene, which disrupt coenzyme Q10 biosynthesis. CASE PRESENTATION: We report the case of a 25-year-old female patient with ADCK4-associated glomerulopathy presenting with proteinuria (and with no additional systemic symptoms). A known missense substitution c.737G > A (p.S246N) and a novel frameshift c.577-600del (p.193-200del) mutation were found. We followed the patient for 24 months during supplementation with coenzyme Q10 (20 mg/kg/d - 30 mg/kg/d) and describe the clinical course. In addition, we measured serum and urine coenzyme Q10 levels before and after coenzyme Q10 supplementation and compared them with those of healthy control subjects. The patient's urinary coenzyme Q10 to creatinine ratio was higher than that of healthy controls before coenzyme Q10 supplementation, but decreased consistently with proteinuria after coenzyme Q10 supplementation. CONCLUSIONS: Although the use of urinary coenzyme Q10 as a diagnostic biomarker and predictor of clinical remission in patients with ADCK4-associated glomerulopathy should be confirmed by larger studies, we recommend measuring urinary coenzyme Q10 in patients with isolated proteinuria of unknown cause, since it may provide a diagnostic clue to mitochondrial nephropathy.
Entities:
Keywords:
ADCK4 mutation; Biomarker; Case report; Coenzyme Q10; Proteinuria
Authors: F Kurogouchi; T Oguchi; E Mawatari; S Yamaura; K Hora; M Takei; Y Sekijima; S i Ikeda; K Kiyosawa Journal: Am J Nephrol Date: 1998 Impact factor: 3.754
Authors: Shazia Ashraf; Heon Yung Gee; Stephanie Woerner; Letian X Xie; Virginia Vega-Warner; Svjetlana Lovric; Humphrey Fang; Xuewen Song; Daniel C Cattran; Carmen Avila-Casado; Andrew D Paterson; Patrick Nitschké; Christine Bole-Feysot; Pierre Cochat; Julian Esteve-Rudd; Birgit Haberberger; Susan J Allen; Weibin Zhou; Rannar Airik; Edgar A Otto; Moumita Barua; Mohamed H Al-Hamed; Jameela A Kari; Jonathan Evans; Agnieszka Bierzynska; Moin A Saleem; Detlef Böckenhauer; Robert Kleta; Sherif El Desoky; Duygu O Hacihamdioglu; Faysal Gok; Joseph Washburn; Roger C Wiggins; Murim Choi; Richard P Lifton; Shawn Levy; Zhe Han; Leonardo Salviati; Holger Prokisch; David S Williams; Martin Pollak; Catherine F Clarke; York Pei; Corinne Antignac; Friedhelm Hildebrandt Journal: J Clin Invest Date: 2013-11-25 Impact factor: 14.808